Medpace (NASDAQ:MEDP) CEO Sells $17,293,477.89 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 27,833 shares of Medpace stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $621.33, for a total transaction of $17,293,477.89. Following the sale, the chief executive officer directly owned 389,456 shares in the company, valued at approximately $241,980,696.48. This trade represents a 6.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Medpace Stock Performance

Shares of NASDAQ:MEDP traded down $1.71 during midday trading on Friday, hitting $618.88. The company’s stock had a trading volume of 229,012 shares, compared to its average volume of 332,429. The business’s 50 day simple moving average is $593.03 and its 200 day simple moving average is $515.26. The company has a market cap of $17.27 billion, a P/E ratio of 36.28, a price-to-earnings-growth ratio of 2.81 and a beta of 1.15. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the prior year, the firm earned $3.10 EPS. Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on MEDP shares. BMO Capital Markets lifted their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Robert W. Baird raised their target price on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Mizuho lifted their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Finally, Royal Bank Of Canada raised their price objective on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus price target of $595.20.

Hedge Funds Weigh In On Medpace

Large investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of Medpace in the second quarter valued at approximately $1,323,047,000. Wasatch Advisors LP grew its stake in Medpace by 19.4% during the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock worth $371,634,000 after buying an additional 125,625 shares during the last quarter. State Street Corp raised its position in Medpace by 4.2% in the 2nd quarter. State Street Corp now owns 710,895 shares of the company’s stock valued at $376,483,000 after purchasing an additional 28,666 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after buying an additional 24,625 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after purchasing an additional 38,760 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.